FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

14 letters match. Newest first.

  1. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  2. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  3. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  4. American Behavioral Research Institute, LLC

    FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.

    High risk
  5. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk
  6. Richard W. Foltin, Ph.D.

    FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.

    High risk
  7. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  8. Tyrone L. McCall, M.D./Cornea Associates of Texas

    FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.

    High risk
  9. Maggie Jeffries, M.D. / Avanti Anesthesiology, LLC

    FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.

    High risk
  10. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  11. Lauren R. Klein, MD, M.S.

    FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.

    High risk
  12. RAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.

    FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.

    High risk
  13. Kaleido Biosciences, Inc.

    Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.

    High risk
  14. KDunn and Associates, P.A. dba HealthQuilt

    Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.

    High risk